M&A Deal Summary

PBM Capital Group Acquires AkaRx

On March 30, 2016, private equity firm PBM Capital Group acquired life science company AkaRx from Eisai

Acquisition Highlights
  • This is PBM Capital Group’s 2nd transaction in the Life Science sector.
  • This is PBM Capital Group’s 2nd transaction in the United States.
  • This is PBM Capital Group’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2016-03-30
Target AkaRx
Sector Life Science
Buyer(s) PBM Capital Group
Sellers(s) Eisai
Deal Type Divestiture

Target

AkaRx

Paramus, New Jersey, United States
AkaRx, Inc. is a developer of Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

PBM Capital Group

Investor Investor Investor Investor Investor

Category Private Equity Firm
Size Small
Type Sector Focused
DESCRIPTION

PBM Capital Group is a private investment firm primarily focused on the healthcare and life science sectors. Prospective transaction types include management buyouts, growth financings, recapitalization, and stake purchases. PBM Capital Group was formed in 2010 and is based in Charlottesville, Virginia.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (New Jersey) 1 of 1
Country (United States) 2 of 2
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-19 AveXis

Dallas, Texas, United States

AveXis is a clinic-ready, synthetic biology platform company. AveXis has several ongoing clinical studies for the treatment of SMA, an inherited neurodegenerative disease caused by a defect in a single gene, the survival motor neuron (SMN1). The lead AveXis gene therapy candidate, AVXS-101, has highly compelling clinical data in treating SMA Type 1, which is the number one genetic cause of death in infants, where 9 out of 10 infants do not live to their second birthday or are permanently ventilator dependent. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-30 Triangle Research Labs

North Carolina, United States

Triangle Research Labs LLC is a hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications.

Sell -

Seller(S) 1

SELLER

Eisai

Woodcliff Lake, New Jersey, United States
Category Company
Founded 1995
Sector Life Science
DESCRIPTION

Eisai, Inc. is a pharmaceutical company focuses on neurology, gastrointestinal disorders and oncology/critical care.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (New Jersey) 1 of 2
Country (United States) 1 of 2
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-01-06 AkaRx

Paramus, New Jersey, United States

AkaRx, Inc. is a developer of Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist.

Buy $255M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-01 Eisai - Two Medicines

Woodcliff Lake, New Jersey, United States

Eisai, Inc. - Two Medicines (Salagen & Panretin) is a pharmaceutical business, Salagen® indications include the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck, and the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. Panretin® indications include the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS).

Sell $33M
Mergr

Product

Company

Legal